Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Amivantamab and hyaluronidase-lpuj |
| Synonyms | |
| Therapy Description |
Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is a subcutaneous formulation of amivantamab, which may lead to improved tolerability and convenience (PMID: 38857463). Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is FDA-approved for use in all indications approved for the intravenous formulation of Rybrevant (amivantamab-vmjw) (FDA.gov). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Amivantamab and hyaluronidase-lpuj | Rybrevant Faspro | EGFR Antibody 74 EGFR Exon 20 Insertion Inhibitor 16 MET Antibody 39 | Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is a subcutaneous formulation of amivantamab, which may lead to improved tolerability and convenience (PMID: 38857463). Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is FDA-approved for use in all indications approved for the intravenous formulation of Rybrevant (amivantamab-vmjw) (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|